<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04363424</url>
  </required_header>
  <id_info>
    <org_study_id>NL71593.068.19</org_study_id>
    <secondary_id>METC 19-080</secondary_id>
    <nct_id>NCT04363424</nct_id>
  </id_info>
  <brief_title>Alcohol Biomarker Study</brief_title>
  <official_title>Phenotypical and Pathophysiological Characterization of Patients With Alcohol-related Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To validate ethyl glucuronide in scalp hair, fingernail and urine as a biomarker&#xD;
      for alcohol use in patients with alcoholic cirrhosis.&#xD;
&#xD;
      Background: Alcoholic cirrhosis is a leading indication for liver transplantation in&#xD;
      abstinent patients. However, the assessment of alcohol use remains a daily diagnostic&#xD;
      challenge. Ethyl glucuronide (EtG) is the most promising biomarker for the detection of&#xD;
      alcohol use. EtG can be both a short-term (urinary EtG) and long-term biomarker (scalp hair&#xD;
      and nail EtG). Although EtG is synthetized in the hepatocyte, the validation of these&#xD;
      biomarkers and their proposed cut-off values is not present or scarce in patients with&#xD;
      cirrhosis, impeding their widespread clinical use.&#xD;
&#xD;
      Therefore, the investigators will assess the diagnostic accuracy of EtG in scalp hair,&#xD;
      fingernail and urine in a cohort of patients with cirrhosis. In addition, the investigators&#xD;
      will apply a new mass spectrometry imaging (MSI) method to visualize the distribution of EtG&#xD;
      in scalp hair, allowing a visual chronological assessment of alcohol intake based on a single&#xD;
      hair strand.&#xD;
&#xD;
      Methods: Blood, proximal scalp hair, fingernail samples and urine will be collected from&#xD;
      patients with alcoholic cirrhosis at the Maastricht University Medical Center. Alcohol intake&#xD;
      in the previous 3 months will be questioned using the Timeline Followback method. The&#xD;
      diagnostic accuracy of hair EtG (analyzed with matrix-assisted laser&#xD;
      desorption/ionization-MSI and routine gas chromatography-tandem mass spectrometry&#xD;
      (GC-MS/MS)), fingernail and urinary EtG (both GC-MS/MS) for moderate and excessive alcohol&#xD;
      use will be assessed in a validation cohort. Secondly, the investigators will assess the&#xD;
      diagnostic potential of these EtG biomarkers in a clinical application group of patients with&#xD;
      alcoholic cirrhosis undergoing screening for liver transplantation.&#xD;
&#xD;
      Anticipated results: The combination of different EtG biomarkers allows accurate assessment&#xD;
      of abstinence and alcohol use in patients with alcoholic cirrhosis and therefore can be&#xD;
      implemented in the daily care of liver patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy of non-invasive alcohol biomarkers (urinary, hair and fingernail ethyl glucuronide) based on self-reported alcohol intake.</measure>
    <time_frame>3 months</time_frame>
    <description>Urine, hair and fingernail samples will be collected at a single point in time. The diagnostic accuray (sensitivity, specificity, positive and negative predictive value) of urine, hair and fingernail ethyl glucuronide will be based on self reported alcohol intake assessed by the alcohol timeline followback method.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">191</enrollment>
  <condition>Alcoholic Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Validation cohort</arm_group_label>
    <description>Patients with alcoholic cirrhosis with reliable self-reported alcohol use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinical application cohort</arm_group_label>
    <description>Patients with alcoholic cirrhosis who deny moderate or excessive alcohol use in the previous 3 months.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with alcoholic liver disease will be included from the in- outpatient clinic of&#xD;
        the Maastricht University Medical Center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of alcoholic liver cirrhosis: consensus of the medical team based on (1) the&#xD;
             patient history alcohol use (2) the exclusion of other causes of liver disease by&#xD;
             blood analysis and (3) if available, liver histology findings.&#xD;
&#xD;
          -  Age &gt; 18 years old.&#xD;
&#xD;
          -  For the validation cohort: reliable self-reported alcohol use. The reliability of this&#xD;
             self-report will be based on (1) an interview by the researcher at study inclusion,&#xD;
             (2) an interview by the physician at inclusion.&#xD;
&#xD;
          -  For the clinical application group: patients with ALD who deny moderate or excessive&#xD;
             alcohol use in the previous 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other liver disease than alcoholic liver cirrhosis: viral hepatitis, auto-immune liver&#xD;
             disease, hereditary hemochromatosis, Wilson's disease and cholestatic liver diseases&#xD;
             (primary biliary cholangitis, primary sclerosing cholangitis) and Î±1-antitrypsine&#xD;
             deficiency.&#xD;
&#xD;
          -  For the validation group: unreliable self-reported alcohol use. Patients will be&#xD;
             excluded in case of any doubt or inconsistency concerning the self-reported alcohol&#xD;
             use.&#xD;
&#xD;
          -  Pregnancy and breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jef Verbeek, MD, PhD</last_name>
    <phone>0032/16.34.47.75</phone>
    <email>jef.verbeek@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ad Masclee, MD, PhD</last_name>
    <phone>0031/433.87.50.21</phone>
    <email>a.masclee@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jef Verbeek, MD, PhD</last_name>
      <phone>0032/16.34.47.75</phone>
      <email>jef.verbeek@uzleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis, Alcoholic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

